KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Current Deferred Revenue: 2009-2025

Historic Current Deferred Revenue for Novavax (NVAX) over the last 15 years, with Sep 2025 value amounting to $501.4 million.

  • Novavax's Current Deferred Revenue fell 55.58% to $501.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $501.4 million, marking a year-over-year decrease of 55.58%. This contributed to the annual value of $1.1 billion for FY2024, which is 29.92% up from last year.
  • As of Q3 2025, Novavax's Current Deferred Revenue stood at $501.4 million, which was down 2.27% from $513.0 million recorded in Q2 2025.
  • Novavax's Current Deferred Revenue's 5-year high stood at $1.6 billion during Q4 2021, with a 5-year trough of $404.8 million in Q3 2022.
  • For the 3-year period, Novavax's Current Deferred Revenue averaged around $849.5 million, with its median value being $863.5 million (2023).
  • As far as peak fluctuations go, Novavax's Current Deferred Revenue spiked by 26,331.38% in 2021, and later plummeted by 68.86% in 2022.
  • Over the past 5 years, Novavax's Current Deferred Revenue (Quarterly) stood at $1.6 billion in 2021, then crashed by 65.56% to $549.6 million in 2022, then spiked by 57.13% to $863.5 million in 2023, then rose by 29.92% to $1.1 billion in 2024, then slumped by 55.58% to $501.4 million in 2025.
  • Its Current Deferred Revenue was $501.4 million in Q3 2025, compared to $513.0 million in Q2 2025 and $517.9 million in Q1 2025.